9. BioMerieux
The BioMérieux Vitek MS [Image courtesy of BioMérieux]
R&D spend: $301.0 million
Percent of revenues: 12.9%
2017 overall revenue rank: 36
BioMérieux (Marcy l’Étoile, France) provides in vitro diagnostics products including reagents, instruments and software. In July, the company announced U.S. FDA 510(k) clearance for its Vitek MS – its MALDI-TOF1 mass spectrometry system – for the expanded identification of mycobacteria, Nocardia and molds. The clearance came after BioMérieux submitted data from a multi-center study consisting of 2,695 clinical isolates for 47 molds, 19 mycobacteria, and 12 Nocardia.
